Brokers Set Expectations for TScan Therapeutics, Inc.’s Q1 2025 Earnings (NASDAQ:TCRX)

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Research analysts at Wedbush issued their Q1 2025 EPS estimates for TScan Therapeutics in a research note issued to investors on Wednesday, April 17th. Wedbush analyst D. Nierengarten expects that the company will post earnings of ($0.26) per share for the quarter. Wedbush currently has a “Outperform” rating and a $10.00 target price on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.04) per share. Wedbush also issued estimates for TScan Therapeutics’ Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.28) EPS and Q4 2025 earnings at ($0.27) EPS.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings results on Wednesday, March 6th. The company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.08. TScan Therapeutics had a negative net margin of 423.86% and a negative return on equity of 60.65%. The firm had revenue of $7.21 million during the quarter, compared to analysts’ expectations of $2.94 million.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of TScan Therapeutics in a report on Thursday, March 7th.

TScan Therapeutics Stock Performance

TScan Therapeutics stock opened at $6.92 on Thursday. TScan Therapeutics has a 52-week low of $1.62 and a 52-week high of $9.00. The firm has a market capitalization of $331.33 million, a P/E ratio of -3.66 and a beta of 0.90. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.51 and a quick ratio of 6.51. The stock has a fifty day moving average price of $7.04 and a two-hundred day moving average price of $5.64.

Institutional Investors Weigh In On TScan Therapeutics

Several institutional investors have recently bought and sold shares of TCRX. Vanguard Group Inc. raised its stake in shares of TScan Therapeutics by 28.9% during the 3rd quarter. Vanguard Group Inc. now owns 1,752,594 shares of the company’s stock worth $4,487,000 after purchasing an additional 393,305 shares in the last quarter. abrdn plc bought a new stake in TScan Therapeutics in the 4th quarter valued at $1,166,000. Renaissance Technologies LLC raised its stake in TScan Therapeutics by 1,171.2% in the 2nd quarter. Renaissance Technologies LLC now owns 147,462 shares of the company’s stock valued at $369,000 after acquiring an additional 135,862 shares during the period. Stifel Financial Corp bought a new stake in TScan Therapeutics in the 2nd quarter valued at $248,000. Finally, Balyasny Asset Management L.P. bought a new stake in TScan Therapeutics in the 4th quarter valued at $268,000. Institutional investors own 82.83% of the company’s stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.